Clinical Trial Finder
Ask About Participating in This Study
ObservationalEnrolling
Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part A), protocol number BEGIN-OB-19 Part AThe following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
(this will open in your email program)
ObservationalEnrolling
Study to evaluate the effects of CFTR modulators in infants and young children (BEGIN Part A), protocol number BEGIN-OB-19 Part A
This two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.
-
Age:
Less than 5 Years
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
6
-
Length of Participation:
3 years
Related Topics
-
Questions to Ask When Considering a Specific Trial
Clinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.
-
Patient Safety Is a Priority
Nothing is more important than patient safety in developing new treatments for cystic fibrosis. The U.S. government requires that all clinical trials are supervised for safety, and the Cystic Fibrosis Foundation adds additional measures to protect study volunteers.
-
Trikafta™
The following is a collection of information and news about Trikafta™, the triple-combination modulator therapy that was approved by the U.S. Food and Drug Administration on Oct. 21, 2019.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More